Sputnik V COVID-19 Vaccine to be Produced in India
Russian Direct Investment Fund (RDIF) and Indian pharma company Hetero, have agreed to produce over 100 million doses per year of Sputnik V covid vaccine in India, Russia's sovereign wealth fund said.
The production of the Russian COVID-19 vaccine is expected to start in the beginning of 2021.
“We are pleased to collaborate with RDIF as a manufacturing partner for the most anticipated Sputnik V vaccine for the tr
eatment of COVID-19. While we look forward to the clinical trial results in India, we believe that manufacturing the product locally is crucial to enable swift access to patients," B. Murali Krishna Reddy, Director – International Marketing, Hetero Labs Limited commented.
RDIF already has a tie-up with another Hyderabad-based pharma biggie Dr Reddy’s Laboratories for conducting Phase 2/3 clinical trials for Sputnik V and for distribution of 100 million doses in the Indian market.
The Russian vaccine has already received the approval of the Indian drug regulators for Phase 2/3 clinical trials even as Phase 3 trials are underway in Belarus, the UAE, Venezuela and other countries.
RDIF said interim trial results confirmed the high efficacy of the Sputnik V vaccine, the world’s first registered vaccine against coronavirus based on a well-studied platform of human adenoviral vectors.
- India News
- COVID19 vaccine
- Russian COVID vaccine
- Sputnik V covid vaccine